Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.
Learn more and read the full article from Drug Topics.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Same mutations linked to breast cancer risk found in black, white women
November 8th 2021A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.
Read More
Aromatase inhibitors for climacteric symptoms in women with breast cancer
July 8th 2020New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.
Read More